Andreas Winterpacht
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Andreas Winterpacht has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
A Schweizer
Institute of Human Genetics, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
1 shared publicationA Tagariello
Institute of Human Genetics, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
1 shared publicationB Swoboda
Division of Orthopaedic Rheumatology, Department of Orthopaedic Surgery, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
1 shared publicationBernhard Zabel
Children's Hospital, University of Mainz, Mainz, Germany
1 shared publicationBerno Tanner
Department of Gynecology, University of Mainz, Mainz, Germany
1 shared publicationBrendan Lee
Department of Molecular and Human Genetics and Howard Hughes Medical Institute, Baylor College of Medicine, Houston TX, USA
1 shared publication
Latest Publications
- 1 February 2007
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 66 (2) , 279-280
MATN3 (matrilin-3) sequence variation (pT303M) is a risk factor for osteoarthritis of the CMC1 joint of the hand, but not for knee osteoarthritis
- 1 February 2007
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 66 (2) , 279-280
MATN3 (matrilin-3) sequence variation (pT303M) is a risk factor for osteoarthritis of the CMC1 joint of the hand, but not for knee osteoarthritis
- Open Access
- 11 April 2005
- Published by Wiley in International Journal of Cancer
- Vol. 116 (4) , 547-554
SPOC1, a novel PHD‐finger protein: Association with residual disease and survival in ovarian cancer
We report the identification of a novel human gene (SPOC1) which encodes a protein with a PHD‐finger domain. The gene is located in chromosomal region 1p36.23, a region implicated in tumor development and progression. RNA in situ hybridization experiments showed strong SPOC1 expression in some rapidly proliferating cell types, such as spermatogonia, but not in nonpro‐liferating mature spermatocytes. In addition, high SPOC1 mRNA expression was observed in several ovarian cancer cell lines. This prompted us to systematically examine SPOC1 expression in ovarian cancer in relation to prognosis. SPOC1 mRNA expression was quantified in tumor tissue of 103 patients with epithelial ovarian cancer. Interestingly, SPOC1 was associated with residual disease, whereby patients with unresectable tumors showed higher levels compared to patients without residual tumor tissue after surgery (p = 0.029). The univariable proportional hazards model showed an association between SPOC1 expression and survival (p = 0.043, relative risk = 1.535). Median survival time was 1,596 days for patients with low SPOC1 expression vs. only 347 days for patients with high expression, using Kaplan‐Meier analysis. However, SPOC1 was not associated with survival when multivariable analysis was adjusted for residual disease. This can be explained by the correlation between residual disease and SPOC1 expression. In conclusion, SPOC1 is a novel PHD‐finger protein showing strong expression in spermatogonia and ovarian cancer cells. SPOC1 overexpression was associated with unresectable carcinomas and shorter survival in ovarian cancer.
- 11 April 2005
- Published by Wiley in International Journal of Cancer
- Vol. 116 (4) , 547-554
Open AccessSPOC1, a novel PHD‐finger protein: Association with residual disease and survival in ovarian cancer
We report the identification of a novel human gene (SPOC1) which encodes a protein with a PHD‐finger domain. The gene is located in chromosomal region 1p36.23, a region implicated in tumor development and progression. RNA in situ hybridization experiments showed strong SPOC1 expression in some rapidly proliferating cell types, such as spermatogonia, but not in nonpro‐liferating mature spermatocytes. In addition, high SPOC1 mRNA expression was observed in several ovarian cancer cell lines. This prompted us to systematically examine SPOC1 expression in ovarian cancer in relation to prognosis. SPOC1 mRNA expression was quantified in tumor tissue of 103 patients with epithelial ovarian cancer. Interestingly, SPOC1 was associated with residual disease, whereby patients with unresectable tumors showed higher levels compared to patients without residual tumor tissue after surgery (p = 0.029). The univariable proportional hazards model showed an association between SPOC1 expression and survival (p = 0.043, relative risk = 1.535). Median survival time was 1,596 days for patients with low SPOC1 expression vs. only 347 days for patients with high expression, using Kaplan‐Meier analysis. However, SPOC1 was not associated with survival when multivariable analysis was adjusted for residual disease. This can be explained by the correlation between residual disease and SPOC1 expression. In conclusion, SPOC1 is a novel PHD‐finger protein showing strong expression in spermatogonia and ovarian cancer cells. SPOC1 overexpression was associated with unresectable carcinomas and shorter survival in ovarian cancer.